a Department of Nephrology, Hypertension and Family Medicine , Medical University of Lodz , Lodz , Poland.
b Department of Nephrology, Hypertension and Family Medicine , WAM Teaching Hospital , Lodz , Poland.
Expert Opin Pharmacother. 2018 Dec;19(17):1857-1865. doi: 10.1080/14656566.2018.1532501. Epub 2018 Oct 9.
Cardiovascular disease (CVD) is an important cause of mortality and morbidity worldwide. CVD morbidity and mortality are associated with significant financial costs related to hospitalization, medication, and lost productivity. The concept of the 'polypill' for the reduction of cardiovascular risk was proposed in 2000. A polypill is a fixed combination of drugs in a single tablet or capsule. The initial polypill consisted of three different classes of antihypertensive drugs (each at half dose), in addition to aspirin, a statin, and folic acid. The challenge today is to produce polypills containing drugs with established efficacy and complementary actions. Areas covered: The authors provide their expert perspectives on the polypill and consider the randomized clinical trials that have evaluated the safety, efficacy, adherence, and cost-effectiveness of polypills. Expert opinion: The polypill makes prescribing easier by reducing the need for complex treatment algorithms and dose titration. It also appears to be cost-effective. However, there are several issues that need to be addressed before the polypill can be used routinely. A single polypill formulation may not be suitable for all patients. It may be necessary to develop several types of polypill to meet the needs of different patient groups.
心血管疾病（CVD）是全球范围内导致死亡率和发病率的重要原因。CVD 的发病率和死亡率与与住院、药物治疗和生产力损失相关的巨大经济成本有关。2000 年提出了降低心血管风险的“复方药”概念。复方药是一种将药物固定在一片或一粒胶囊中的混合物。最初的复方药由三种不同类别的降压药（每种药物的剂量减半）组成，此外还有阿司匹林、他汀类药物和叶酸。今天的挑战是生产含有具有明确疗效和互补作用的药物的复方药。涵盖领域：作者就复方药提供了他们的专业观点，并考虑了评估复方药安全性、疗效、依从性和成本效益的随机临床试验。专家意见：复方药通过减少对复杂治疗算法和剂量滴定的需求，使处方更简单。它似乎也具有成本效益。然而，在常规使用复方药之前，还有几个问题需要解决。单一的复方药制剂可能并不适合所有患者。可能需要开发几种类型的复方药来满足不同患者群体的需求。
